Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Core Insights - Ernexa Therapeutics is advancing its lead cell therapy ERNA-101 for ovarian cancer through a partnership with Cellipont Bioservices [3] - The company specializes in innovative cell therapies targeting advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) [4] Company Overview - Ernexa Therapeutics (NASDAQ: ERNA) focuses on developing novel cell therapies for advanced cancer and autoimmune diseases [4] - The company's technology involves engineering iPSCs into induced mesenchymal stem cells (iMSCs), providing scalable treatment solutions without the need for patient-specific cell harvesting [4] Product Details - ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells [5] - ERNA-201 targets inflammation to treat autoimmune diseases, with the initial focus on developing ERNA-101 for ovarian cancer [5]